Cervical Cancer Drugs Market - Size, Share,
Outlook, and Opportunity Analysis, 2018-2026
Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged
between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death
rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a
screening procedure which can detect the changes in the cervix before the cancer develops. There
are different types of cervical cancer, out of which two main types are squamous cell cancer and
adenocarcinoma.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1746
Cervical Cancer Drugs Market Drivers
Increasing number of drug approval done by U.S. Food and Drug Administration (FDA) for the
treatment of cervical cancer is expected to drive growth of the cervical cancer drugs market over the
forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA)
approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of
multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi
is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, U.S. FDA
approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in
combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.
Furthermore, increasing funding for cancer research, rising insurance coverage, and increase in the
number of new targeted cancer drugs are expected to support the revenue growth of cervical cancer
drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on
cancer research, which include cervical cancer, lung cancer, colorectal cancer, liver cancer, breast